G Gurumurthy,J Kropidlowska,L Reynolds et al.
G Gurumurthy et al.
Targeted inhibition of the mitogen-activated protein kinase (MAPK) pathway with BRAF inhibitors has been crucial in improving outcomes for BRAF-variant melanoma. However, clinically significant bleeding has recently been reported in the lit...
Local Control With Moderately Hypofractionated Definitive Radiotherapy Delivered With a Simultaneous Integrated Boost Technique to Non-extremity Soft Tissue and Bone Sarcomas [0.03%]
采用同期整合补量技术对非四肢软组织肉瘤及骨肿瘤实施中等低分割根治性放疗的局部控制效果研究
J D Towler,C David,O Willis et al.
J D Towler et al.
Aims: While surgery is the primary treatment for soft tissue sarcomas (STS) and primary bone sarcomas, a notable proportion of patients with non-extremity tumours do not undergo resection. Outcome data for definitive radi...
Immune Checkpoint Inhibitor Therapy for Advanced, Unresectable Esophageal Squamous Cell Carcinoma: A Series of Patient-level Meta-analyses From Phase III Trials [0.03%]
基于III期临床试验的晚期不可切除食管鳞癌免疫检查点抑制剂治疗的真实世界研究：患者级别meta分析
M S Beshr,R H Shembesh,M V Nounou et al.
M S Beshr et al.
Aim: This study reconstructed patient-level data to provide updated evidence on survival outcomes across PD-L1 expression subgroups. Materials and methods...
N Varmenot,K Sjögreen Gleisner,J Taprogge et al.
N Varmenot et al.
In recent years the treatment of cancer with radioactive drugs, here termed molecular radiotherapy (MRT), has emerged to take a place alongside other treatment modalities, particularly non-radioactive drugs (NRDs) and external beam radiothe...
Two Versus Five-Fraction Magnetic Resonance-Guided Adaptive Radiotherapy with DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2): Interim Acute Toxicity Analysis of the Phase II Randomised Trial [0.03%]
针对局灶性前列腺癌的两项适应性放射治疗(基于磁共振引导的主要靶区强化)的二期随机试验(DOTA-2)：中期急性毒性分析
R Romrattaphan,P Dankulchai,T Prasartseree et al.
R Romrattaphan et al.
Aims: DOminant-TArgeted Boost in Localized Prostate Cancer (DOTA-2) is a phase II randomised controlled trial comparing two ultra-hypofractionated radiotherapy with dominant intraprostatic lesion (DIL) boost: 26 Gy/2F, 32...
Safety and Efficacy of Nivolumab Plus Ipilimumab in Microsatellite Instability-High/Mismatch Repair-Deficient Colorectal Cancer: A Systematic Review [0.03%]
纳武单抗联合伊匹莫桑治疗微卫星不稳定型/错配修复型结直肠癌的疗效和安全性：一项系统综述研究
E Kokori,I C Abraham,G Olatunji et al.
E Kokori et al.
Aims: Colorectal cancer (CRC) remains a significant global health burden, with rising incidence and mortality despite advances in screening and treatment. Microsatellite instability-high (MSI-H) and mismatch repair-defici...